Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pre-miR-204
- Development stage
- Preclinical
- Lead developer
- The Chinese University of Hong Kong
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Subcutaneous, Intravenous, Intraperitoneal, Intranasal
01
Overview
pre-miR-204 is a precursor microRNA molecule that serves as a template for the production of mature miR-204, a small non-coding RNA involved in post-transcriptional gene regulation. In various malignancies, including endometrioid endometrial adenocarcinoma (EEC), miR-204 is frequently downregulated and functions as a tumor suppressor. The administration of synthetic pre-miR-204 (miRNA mimics) is an experimental therapeutic approach designed to restore miR-204 levels, thereby inhibiting oncogenic processes such as cell migration, invasion, and epithelial-mesenchymal transition. Research indicates that miR-204 signatures can serve as diagnostic or prognostic markers, and its restoration via pre-miR-204 represents a potential strategy for targeted cancer therapy by modulating downstream signaling pathways involved in tumor progression.
- Other names
- pre-microRNA-204pre-microRNA204pre-microRNA 204miR-204 precursormiR204 precursormiR 204 precursormicroRNA-204 precursormicroRNA204 precursormicroRNA 204 precursormiR-204 mimicmiR204 mimicmiR 204 mimic
02
Targets
Endoribonuclease Dicer–TAR RNA-binding protein 2 complexXPO5 (Exportin-5)TGFBR2 (TGF-β receptor type 2)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)Microprocessor (Drosha–DGCR8 microprocessor complex)AGO2 (Argonaute RISC catalytic component 2)BCL-2 (BCL-2 family)Meis homeobox 2 mRNASOX4 (SRY-box transcription factor 4)
Beyond the preview
Go deeper on pre-miR-204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pre-miR-204.